Literatur
- 1
Collet J P, Hulot J S, Pena A. et al .
Cytochrome P450 2C19 polymorphism
in young patients treated with clopidogrel after myocardial infarction:
a cohort study.
Lancet.
2009;
373
309-317
- 2
Connolly S J, Pogue J, Hart R G. et al .
Effect of Clopidogrel Added to Aspirin
in Patients with Atrial Fibrillation.
N Engl J Med.
2009;
360
2066-2078
- 3
Disertori M, Latini R, Barlera S. et al .
Valsartan for prevention of recurrent atrial
fibrillation.
N Engl J Med.
2009;
360
1606-1617
- 4
Fellstrom B C, Jardine A G, Schmieder R E. et al .
Rosuvastatin and cardiovascular
events in patients undergoing hemodialysis.
N Engl J Med.
2009;
360
1395-1407
- 5
Hohnloser S H, Crijns H J, van Eickels M. et al .
Effect of dronedarone on
cardiovascular events in atrial fibrillation.
N Engl J
Med.
2009;
360
668-678
- 6
Massie B M, Carson P E, McMurray J J. et al .
Irbesartan in patients with
heart failure and preserved ejection fraction.
N Engl
J Med.
2008;
359
2456-2467
- 7
Mega J L, Close S L, Wiviott S D. et al .
Cytochrome p-450 polymorphisms
and response to clopidogrel.
N Engl J Med.
2009;
360
354-362
- 8
O’Connor C M, Whellan D J, Lee K L. et al .
Efficacy and safety
of exercise training in patients with chronic heart failure: HF-ACTION
randomized controlled trial.
JAMA.
2009;
301
1439-1450
- 9
Ridker P M, Danielson E, Fonseca F A. et al .
Rosuvastatin to prevent vascular events
in men and women with elevated C-reactive protein.
N Engl J
Med.
2008;
359
2195-2207
- 10
Ridker P M, Danielson E, Fonseca F A. et al .
Reduction in C-reactive protein and LDL
cholesterol and cardiovascular event rates after initiation of rosuvastatin:
a prospective study of the JUPITER trial.
Lancet.
2009;
373
1175-1182
- 11
Roy D, Talajic M, Nattel S. et
al .
Rhythm control versus rate control for atrial fibrillation
and heart failure.
N Engl J Med.
2008;
358
2667-2677
- 12
Simon T, Verstuyft C, Mary-Krause M. et al .
Genetic determinants of response to clopidogrel
and cardiovascular events.
N Engl J Med.
2009;
360
363-375
- 13
Tavazzi L, Maggioni A P, Marchioli R. et al .
Effect of rosuvastatin
in patients with chronic heart failure (the GISSI-HF trial): a randomised,
double-blind, placebo-controlled trial.
Lancet.
2008;
372
1231-1239
Prof. Dr. med. Uta C. Hoppe
Klinik III für Innere Medizin, Universität
zu Köln
Kerpener Straße 62
50937
Köln
Phone: 0221/47832396
Fax: 0221/47832397
Email: Uta.Hoppe@uni-koeln.de
